Protalix (PLX) - Forward P/S Multiple

Graphic logo of Protalix (PLX)

The expected revenue multiple reflects market optimism, with the 8.00 figure serving as the target level for Protalix BioTherapeutics (PLX). Growth is driven by the implementation of ProCellEx automated bioreactors, which eliminate defects. The strategy relies on the joint development of drugs with major partners. Independence from macroeconomic trends makes this sector a defensive asset, ensuring a steady flow of capital into innovations for treating rare pathologies.

PLX Protalix BioTherapeutics, Inc.: Forward Price to Sales in the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Protalix BioTherapeutics, Inc (PLX)

- current price and projected stock value:
Stock Price Protalix BioTherapeutics, Inc.|PLX - Fair Value Consensus
- market capitalization indicators:
Market Capitalization Protalix BioTherapeutics, Inc|PLX - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Protalix BioTherapeutics|PLX - Accounting Value of Company|Market Value to Book Value Ratio protalix.com|PLX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Protalix BioTherapeutics|PLX - Long-Term Debt to Capital|Short-Term Debt to Equity Protalix BioTherapeutics|PLX - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Protalix BioTherapeutics, Inc|PLX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Protalix BioTherapeutics|Quick Liquidity Indicator protalix.com
- business earnings and investment ratios data:
PLX - Profit After Payment of Taxes|Projected Future Earnings Protalix BioTherapeutics|PLX - P/E Multiple|Future Price to Earnings Protalix|PLX - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Protalix BioTherapeutics, Inc|PLX - Operating income before deduction of amortization|Net earnings per share for the last 12 months Protalix BioTherapeutics|PLX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months protalix.com|PLX - Earnings per share increase in current year|Earnings growth forecast for next year Protalix BioTherapeutics
- company sales and revenue statistics:
PLX - Company Revenue|Projected Sales Volume Protalix BioTherapeutics, Inc.|PLX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Protalix BioTherapeutics, Inc
Fundamental valuation:PLX (Protalix BioTherapeutics, Inc.)
Product sample of Protalix BioTherapeutics

A conservative investor assesses the fundamental value of Protalix BioTherapeutics (PLX) through the lens of potential future cash flow capitalization. The expected P/S multiple relates the current market value of the business to projected revenue, which allows this chart to determine the extent of the overpayment for the unique capacities of the Israeli protein expression plant and evaluate the sustainability of the control premium over the assets.

Key competitors

Forward P/S Multiple VRTX (Vertex)|Forward Price to Sales ALNY|Insmed Inc - Forward P/S Multiple|UTHR - Forward P/S Multiple|BioMarin Pharmaceutical (BMRN) - Price-to-Projected Revenue Ratio|bridgebio.com - Forward Price to Sales|Price-to-Projected Revenue Ratio BGM Group Limited|Forward Price-to-Revenue Multiple Cogent Biosciences Inc (COGT)|Forward P/S Multiple XERS|Forward P/S Multiple Keros Corp (KROS)|Price-to-Projected Revenue Ratio Arcturus Therapeutics ARCT|ETON (etonpharma.com) - Future Price to Revenue|KMDA - Price-to-Projected Revenue Ratio|Forward Price to Sales FULC (Fulcrum Therapeutics Inc)|abeonatherapeutics.com (ABEO) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Mereo BioPharma Group plc (MREO)|Forward Price-to-Revenue Multiple PLRX|APLT (appliedtherapeutics.com) - Price to Expected Revenue Ratio|Forward P/S Multiple RNTX|Forward P/S Multiple gelteq.com (GELS)|Price-to-Projected Revenue Ratio Aytu BioPharma AYTU|Chemomab Therapeutics Ltd - Price-to-Projected Revenue Ratio|SRx Health - Forward P/S Multiple|Market Cap to Expected Sales Ratio Polyrizon Ltd PLRZ|AEZS (zentaris.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue CYTH|Forward Price-to-Revenue Multiple INZY|RPHM: Forward Price to Sales|Forward P/S Multiple CSCI